Skip to main content
Clinical Trials/NCT05574140
NCT05574140
Recruiting
Not Applicable

BreathinG-induced Myocardial and Cerebral Perfusion in Anxiety Disorders (B-GLAD)

McGill University Health Centre/Research Institute of the McGill University Health Centre1 site in 1 country84 target enrollmentJuly 15, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Generalized Anxiety Disorder
Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Enrollment
84
Locations
1
Primary Endpoint
Change in Signal Intensity
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

This study aims to view variations in MRI measurements of the heart and the brain in people with anxiety versus healthy volunteers. The MRI measurements used will be Oxygenation-Sensitive Cardiac MRI (OS-CMR), a recent type of MRI which is safe, fast, and non-invasive.

Detailed Description

The investigators will prospectively analyze OS-CMR data from patients with a generalized anxiety disorder from one site. The investigators will observe how an anxiety disorder affects the OS-CMR data. In a follow-up MRI scan, the investigators will look at the OS-CMR of a subgroup who have anxiety disorder and are also undertaking cognitive behavioural therapy to asses how and if this therapy affects the OS-CMR data.

Registry
clinicaltrials.gov
Start Date
July 15, 2022
End Date
September 15, 2025
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Responsible Party
Principal Investigator
Principal Investigator

Matthias Friedrich

Principal Investigator

McGill University Health Centre/Research Institute of the McGill University Health Centre

Eligibility Criteria

Inclusion Criteria

  • Patient population:
  • Confirmation of an anxiety disorder as identified by the PSWQ,
  • No known, current or history, of significant medical conditions that may affect or directly involve the neurological, cardiovascular or respiratory system (except anxiety and depression)
  • Non-smoker
  • Healthy Volunteers:
  • Age 18-55
  • No known, current or history, of significant medical conditions that may affect or directly involve the neurological, cardiovascular or respiratory system
  • Non-smoker

Exclusion Criteria

  • General MRI contraindications: pacemakers, defibrillating wires, implanted defibrillators, intracranial aneurysm clips, metallic foreign bodies in the eyes, pregnancy
  • History of significant neurological disease or illness that is not anxiety (e.g. Dementia, stroke)
  • Hemodynamically unstable conditions
  • Significant or uncontrolled arrhythmias
  • Severe pulmonary disease
  • Recent (\<90 days) myocardial infarction
  • Recent (\<90 days) surgery or coronary intervention
  • Consumption of caffeine (caffeinated beverages, coffee, tea, cocoa, chocolate) within 12h of the exam
  • Use of benzodiazepines or other short-acting anxiety medications (\<1 day)

Outcomes

Primary Outcomes

Change in Signal Intensity

Time Frame: Baseline

Change in signal intensity between the baseline signal intensity and the signal intensity at 30 seconds of breath hold

Study Sites (1)

Loading locations...

Similar Trials